Shire Faces Consumer Antitrust Claims Over Adderall

Law360, New York (April 2, 2013, 7:56 PM EDT) -- Consumers in Pennsylvania and Florida hit Shire US Inc. with a pair of putative class actions this week accusing the pharmaceutical company of illegally stifling competition for Adderall XR, its blockbuster treatment for attention deficit hyperactivity disorder, with patent settlements and supply agreements with generic rivals.

Both cases focus on so-called pay-for-delay settlements that Shire inked with generics makers Teva Pharmaceuticals USA Inc. and Impax Laboratories Inc. to resolve allegations that the two companies' efforts to market a generic version of Adderall would violate Shire's patents....
To view the full article, register now.